LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

441.98 0.11

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

426.11

Максимум

445.59

Ключови измерители
By Trading Economics
Приходи	56M -59M
Продажби	34M 321M
Марж на печалбата	-18.243
Служители	915
EBITDA	56M -50M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+58.26% upside

Дивиденти
By Dow Jones
Следващи печалби	30.04.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-442M 10B
Предишно отваряне	441.87
Предишно затваряне	441.98

Настроения в новините

By Acuity

50%

171 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.03.2026 г., 22:51 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18.03.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18.03.2026 г., 20:31 ч. UTC

Печалби

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18.03.2026 г., 23:31 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery -- Market Talk

18.03.2026 г., 22:49 ч. UTC

Пазарно говорене

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18.03.2026 г., 22:36 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18.03.2026 г., 22:24 ч. UTC

Печалби

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18.03.2026 г., 21:58 ч. UTC

Печалби

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18.03.2026 г., 21:16 ч. UTC

Пазарно говорене

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18.03.2026 г., 21:00 ч. UTC

Значими събития в новините

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18.03.2026 г., 20:58 ч. UTC

Печалби

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18.03.2026 г., 20:41 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:29 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:25 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18.03.2026 г., 20:14 ч. UTC

Пазарно говорене

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18.03.2026 г., 20:09 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18.03.2026 г., 20:07 ч. UTC

Печалби

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18.03.2026 г., 20:06 ч. UTC

Печалби

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Gross Margin About 81% >MU

18.03.2026 г., 20:03 ч. UTC

Печалби

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

58.26% нагоре

12-месечна прогноза

Среден 697.67 USD 58.26%

Висок 964 USD

Нисък 529 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

171 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.